2. Academic Validation
  3. Unexpected in vivo activity of ceftazidime alone and in combination with avibactam against New Delhi metallo-β-lactamase-producing Enterobacteriaceae in a murine thigh infection model

Unexpected in vivo activity of ceftazidime alone and in combination with avibactam against New Delhi metallo-β-lactamase-producing Enterobacteriaceae in a murine thigh infection model

  • Antimicrob Agents Chemother. 2014 Nov;58(11):7007-9. doi: 10.1128/AAC.02662-14.
Shawn H MacVane 1,  Jared L Crandon 1,  Wright W Nichols 2,  David P Nicolau 3
Affiliations

Affiliations

  • 1 Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA.
  • 2 AstraZeneca Pharmaceuticals LP, Waltham, Massachusetts, USA.
  • 3 Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA Division of Infectious Diseases, Hartford Hospital, Hartford, Connecticut, USA david.nicolau@hhchealth.org.
PMID: 25223998 DOI: 10.1128/AAC.02662-14
Abstract

The emergence of the New Delhi Metallo-β-lactamase (NDM) among Enterobacteriaceae has become a global concern because of its high levels of in vitro resistance to nearly all available Antibiotics. However, recent in vivo studies demonstrated the efficacies of carbapenems against NDM-1-producing isolates despite high MICs. Herein, we report in vivo findings with ceftazidime and ceftazidime-avibactam against an isogenic pair (wild type and NDM-1) and four clinical NDM-producing isolates that demonstrate discordance between MICs measured in vitro and the in vivo activity of ceftazidime-avibactam against this resistant genotype.

Figures
Products